Indaptus Therapeutics (NASDAQ:INDP) Trading Up 6.9% – Here’s Why

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) shot up 6.9% during trading on Wednesday . The stock traded as high as $2.0150 and last traded at $2.01. 32,327 shares changed hands during trading, a decline of 32% from the average session volume of 47,822 shares. The stock had previously closed at $1.88.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on INDP shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Indaptus Therapeutics Price Performance

The firm has a market capitalization of $4.14 million, a P/E ratio of -0.06 and a beta of 0.97. The stock’s fifty day simple moving average is $2.35 and its 200 day simple moving average is $3.03.

Hedge Funds Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.